Management of Involuntary Chewing in Late 80s Patient on Neuroleptics
In a patient in their late 80s on neuroleptic therapy who develops involuntary chewing (orofacial dyskinesia), you should immediately treat with a VMAT2 inhibitor such as valbenazine or deutetrabenazine, as this represents moderate-to-severe tardive dyskinesia requiring first-line pharmacological intervention 1.
Diagnostic Confirmation
This presentation is classic for tardive dyskinesia (TD) - specifically buccolingual masticatory syndrome - characterized by involuntary orofacial movements including lip smacking, chewing, and tongue protrusion 2, 3. The key diagnostic features to confirm:
- Timing: TD typically appears after ≥3 months of antipsychotic exposure (unlike drug-induced parkinsonism which occurs within hours to weeks) 3
- Movement pattern: Involuntary choreoathetoid movements predominantly affecting the orofacial region 4
- Assessment: Document severity using the Abnormal Involuntary Movement Scale (AIMS) 2
Critical caveat: In elderly patients (especially late 80s), TD prevalence is significantly higher and the condition may be permanent even after discontinuation 3. Additionally, withdrawal TD can present even 3 months after stopping antipsychotics 5.
Treatment Algorithm
Step 1: Initiate VMAT2 Inhibitor Immediately
The APA guideline provides a 1B recommendation (strong evidence) that patients with moderate-to-severe or disabling tardive dyskinesia be treated with a reversible VMAT2 inhibitor 1. Options include:
- Valbenazine or Deutetrabenazine 3
- These agents reduce dopamine signaling dysregulation without directly blocking D2 receptors 2
- They are effective in managing symptoms in many patients and represent the current standard of care 2, 6
Step 2: Evaluate Antipsychotic Necessity and Adjustment
While treating TD, simultaneously assess:
- Can the antipsychotic be discontinued? If the underlying psychiatric condition allows, gradual reduction or discontinuation may help, though TD may persist or worsen initially 6, 4
- If antipsychotic must continue: Switch from first-generation to second-generation antipsychotic with lower TD risk 6, 7
Step 3: Avoid Common Pitfalls
DO NOT use anticholinergic agents (like benztropine or trihexyphenidyl) as first-line treatment in this scenario. Here's why this is critical:
- Anticholinergic medications can worsen TD 3
- While one case report showed response to scopolamine 9 and another to trihexyphenidyl 7, these represent atypical presentations or possible misdiagnosis
- The evidence strongly indicates anticholinergics are contraindicated in TD, though they're appropriate for drug-induced parkinsonism 3
- In elderly patients, anticholinergic burden significantly worsens cognitive function 8
Alternative and Adjunctive Options
If VMAT2 inhibitors are unavailable, ineffective, or not tolerated, consider:
- Amantadine: Non-anticholinergic agent that may be helpful, particularly if comorbid parkinsonism exists 3, 4
- Other agents with limited evidence: Gabapentin, benzodiazepines (use judiciously in elderly), levetiracetam 4
- Deep brain stimulation: For treatment-resistant cases 2, 6
Monitoring Considerations
Given the patient's advanced age (late 80s):
- Assess renal and hepatic function before initiating VMAT2 inhibitors
- Monitor for worsening parkinsonism (VMAT2 inhibitors can cause this)
- Evaluate fall risk, as movement disorders increase this substantially in elderly patients
- Document baseline and follow-up AIMS scores to track response
Evidence Quality Note
The 2020 APA guideline 1 provides the strongest recommendation (1B) for VMAT2 inhibitors in moderate-to-severe TD, supported by the 2025 INTEGRATE guidelines 8 and recent research 2, 3. This represents a paradigm shift from older approaches that relied on anticholinergics or benzodiazepines, which have poor efficacy and significant risks in elderly patients 4.